Kobayashi Reiko, Yamashita Hideomi, Okuma Kae, Ohtomo Kuni, Nakagawa Keiichi
Department of Radiology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
J Gynecol Oncol. 2016 Mar;27(2):e16. doi: 10.3802/jgo.2016.27.e16. Epub 2015 Oct 8.
This is a retrospective study aimed at clarifying the details of recurrence patterns and sites in patients with cervical cancer treated with definitive radiation therapy (RT).
Data were analyzed from consecutive patients, admitted to the University of Tokyo Hospital (Tokyo, Japan) between 2001 and 2013, who had received definitive RT, with or without chemotherapy, for International Federation of Gynecology and Obstetrics stages IB-IVA cervical cancer.
One hundred and thirty-seven patients formed the patient cohort. The median follow-up period for surviving patients was 57.0 months. A complete response was achieved in 121 patients (88%). Of these, 36 (30%) developed a cancer recurrence during follow-up. The first sites of recurrence were located in intra-RT fields in nine, outside RT fields in 20, and both in seven patients. In the intra-RT field group, all patients showed a local recurrence, while no one experienced an isolated pelvic lymph node (PLN) recurrence. In the outside RT field group, the most frequent site of recurrence was lung (60%), and three-quarters of patients were free from intra-RT field recurrence until the last follow-up. Of the entire cohort, including 48 PLN-positive patients, only seven patients (5.1%) developed PLN persistence or recurrence, all in the common iliac, internal iliac, and/or obturator nodes, and all with another synchronous relapse.
Local disease was a major type of intra-RT field recurrence, while PLN control was favorable even in initially PLN-positive patients. The predominance of outside RT field recurrence alone highlights issues concerning distant control, including the intensity enhancement of systematic therapy.
本研究为回顾性研究,旨在明确接受根治性放疗(RT)的宫颈癌患者复发模式及部位的详细情况。
分析2001年至2013年间收治于东京大学医院(日本东京)的连续患者的数据,这些患者因国际妇产科联盟(FIGO)分期为IB-IVA期的宫颈癌接受了根治性RT,无论是否接受化疗。
137例患者构成研究队列。存活患者的中位随访期为57.0个月。121例患者(88%)达到完全缓解。其中,36例(30%)在随访期间出现癌症复发。复发的首发部位在放疗野内的有9例,放疗野外的有20例,放疗野内外均有的有7例。在放疗野内组,所有患者均表现为局部复发,而无一例出现孤立的盆腔淋巴结(PLN)复发。在放疗野外组,最常见的复发部位是肺(60%),四分之三的患者直至最后一次随访时均无放疗野内复发。在整个队列中,包括48例PLN阳性患者,只有7例(5.1%)出现PLN持续存在或复发,均位于髂总、髂内和/或闭孔淋巴结,且均伴有另一处同步复发。
局部病变是放疗野内复发的主要类型。即使是初始PLN阳性的患者,PLN控制情况也较好。单纯放疗野外复发占优势凸显了远处控制方面的问题,包括全身治疗强度的提高。